334 results about "Serum samples" patented technology

The invention relates to a construction method of a metabolic syndrome phlegm syndrome lipid metabolism characteristic diagnosis model. The construction method comprises the following steps: S1, acquiring a serum sample; s2, carrying out lipid metabolite analysis through a full-quantitative lipidomics formula; s3, carrying out primary screening on differential metabolites; s4, optimizing the characteristic indexes by using a random forest algorithm and stepwise regression; and S5, constructing a differential metabolite diagnosis model through Logistic regression analysis. By analyzing differential lipid metabolites of patients with MetS phlegm syndromes and non-phlegm syndromes, the invention reveals that abnormal accumulation of lipid and lipid metabolites may be the core pathological parenchyma of MetS phlegm syndromes. By integrating lipid metabonomics data, using a random forest algorithm, stepwise regression and other methods to screen feature difference lipid metabolites and construct a MetS phlegm syndrome specific diagnosis model, a novel combined biomarker and evidence-based basis are provided for early diagnosis of MetS phlegm syndromes, and a scientific basis can also be provided for objective diagnosis of traditional Chinese medicine phlegm syndromes.

The invention belongs to the technical field of liquid chromatography-mass spectrometry detection pretreatment, and particularly relates to a pretreatment method for liquid chromatography-tandem mass spectrometry analysis of pesticide and veterinary drug residues in serum, which comprises the following steps: (S1) carrying out heating reaction on Sc (III) salt, Cu (II) salt and 1H-pyrazole-4-formic acid (H2PyC) in a polar aprotic solvent, and cooling to obtain a green crystal, namely MOF-919; the chemical formula of the MOF-919 is [Sc < 3 > (mu3-O) (OH) < 3 >] [Cu3 (mu3-O) (mu-PyC) < 3 > (H2O) < 6 >] < 2 >; (S2) mixing the serum sample with an acetonitrile solution containing formic acid, carrying out ultrasonic treatment, vortex oscillation and centrifugation, taking supernate, and diluting the supernate with an aqueous solution containing formic acid to obtain a to-be-purified solution; and (S3) adding MOF-919 into the to-be-purified liquid, mixing, performing ultrasonic treatment, performing vortex oscillation, centrifuging, and taking supernate, thereby completing the pretreatment of the to-be-purified liquid. According to the method, the MOF-919 is used for adsorbing chemical pollutant residues in serum, especially phospholipids, so that the purpose of removing the chemical pollutant residues in blood is achieved. The method is simple and convenient to operate, small in organic solvent consumption and good in purification effect, and can be widely applied to residue analysis of chemical pollutants in serum.

The invention provides a method for detecting an external vesicle marker through high-flux nano plasma exciting light immune color development, and belongs to the technical field of human extracellular vesicles. After a serum sample is subjected to centrifugal treatment, the serum sample and a CD81 capture antibody substrate are incubated, and the particle size distribution of the vesicles is monitored in real time; a zwitterionic polymer modified gold nanoparticle LAM detection probe and a polyethylene glycol modified silver nanoparticle LprG detection probe are prepared to be specifically combined with a vesicle surface antigen, a chromogenic enhancement solution is adopted to induce a plasma resonance signal, and full-hole scanning imaging is carried out; and constructing a double-layer game optimization model to cooperatively optimize the detection sensitivity and the signal stability, carrying out weighted summation on normalized signals of the particle size subgroups to obtain comprehensive detection signal intensity, comparing the comprehensive detection signal intensity with a threshold value, and outputting a final judgment result. The technical problem that quantitative accuracy is affected by signal intensity deviation caused by vesicle particle size difference in outer vesicle marker detection is solved.

The invention relates to the technical field of spectral analysis and biomedical detection, and discloses an SERS (Surface Enhanced Raman Scattering) spectrum quantitative detection method and system based on interpretable stacked ensemble learning. The method comprises the following steps: acquiring SERS spectral data of serum tumor marker standard substances with different concentration gradients; performing baseline correction and normalization preprocessing on the data, performing sparse feature selection by using an LASSO algorithm, and screening out key spectral features to construct a sample data set; constructing an interpretable stacking integration model, wherein the model adopts a base learner layer and a meta learner layer; training the model by using the training set, optimizing model hyper-parameters by using a cross validation strategy, and establishing a mapping relationship between spectral features and tumor marker concentrations; and collecting SERS spectral data of a to-be-detected serum sample, extracting key spectral features, inputting the key spectral features into the trained interpretable stacked integrated model, and outputting a concentration predicted value of the tumor marker in the to-be-detected serum sample. The method has the advantages of high precision, universality and molecular level interpretability.

The invention belongs to the technical field of biological detection, and particularly relates to a method for synchronously and quantitatively detecting various folic acid metabolism related substances in trace plasma or serum, which comprises the following steps of: detecting a pretreated trace plasma or serum sample by adopting a liquid chromatography-tandem mass spectrometry method; the following nine folic acid metabolism related substances are synchronously and quantitatively detected: 5-formyl tetrahydrofolic acid, folic acid, 5-methyl tetrahydrofolic acid, S-adenosine-L-methionine, S-adenosine-L-homocysteine, vitamin B12, pyridoxamine, pyridoxine and pyridoxal. The invention further relates to application of the detection method in related detection of child neurodevelopment. According to the detection method, only trace plasma or serum is used, methotrexate is used for replacing an expensive isotope internal standard for more economical detection, and nine folate metabolism related substances can be accurately quantified at the same time. Therefore, the detection method disclosed by the invention has important clinical significance and wide market application prospect.

The invention relates to the field of biological detection, in particular to application of IGSF1 protein as a cardiac function recovery marker. The invention provides application of protein as a marker in preparation of a product for detecting and / or diagnosing heart failure with improved ejection fraction. The protein comprises one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4, and is characterized in that the protein comprises one or more of the IGSF1, the LIMS1, the MPP1, the PTX3, the SLC2A3, the FERMT3, the ARPC1B, the IGHG1 The invention provides a novel serum marker, the expression level of the novel serum marker can predict heart failure patients with reduced ejection fraction and heart function recovery potential with high precision, and the change of the novel serum marker is earlier than the change of ejection fraction. According to the invention, a non-invasive standardized detection process based on a serum sample is established, all levels of medical institutions are adapted, and early and non-invasive prediction of the heart function recovery potential of the heart failure patient is realized.

The invention discloses a stem cell metabolism marker omics analysis method, device, equipment and medium, relates to the technical field of biomedicine, is applied to a computer device, and comprises the following steps: carrying out non-targeted detection on a to-be-detected sample of a target object to obtain an original mass spectrum; wherein the sample to be detected is a serum sample or a cell sample; preprocessing the original mass spectrogram to obtain a metabolite matrix in a standardized format; performing principal component analysis and partial least square discriminant analysis on the metabolite matrix, and determining a metabolic marker from the metabolite matrix according to an obtained analysis result; obtaining fragment information of the metabolic marker based on a collision-induced dissociation mode, and searching for a structural annotation of the metabolic marker from a human metabolome database based on the fragment information; and constructing a metabolic pathway map of the metabolic marker according to the structural annotation of the metabolic marker. The accuracy of omics analysis of the stem cell metabolism marker is improved.

The invention discloses a cadmium ion and lead ion detection system and method based on CRISPR and deoxyribozyme, and the method comprises the following steps: forming active deoxyribozyme by using target ions and a recognition probe, cutting a redundant sequence in a substrate probe, releasing a semi-activator, and cooperatively activating the activity of CRISPR-Cas12a with the other semi-activator in the system. According to the system, the signal-to-noise ratio and the sensitivity of detection are improved by utilizing the effect of inhibiting cooperative activation by redundant fragments in semi-activators. According to the detection method, nano material modification on the substrate probe is not needed, magnetic separation is not needed, and the detection cost is reduced. The detection process only needs two steps of room temperature incubation reaction, and the two steps are carried out in one reaction tube, so that cross contamination possibly caused by multi-tube reaction is avoided, and the detection process is simplified. The method can be applied to detection of cadmium ions and lead ions in rice or serum samples, and has wide application prospects in the fields of food safety, medical detection and the like.

The invention discloses a combined reagent for detecting fungus (1-3)-beta-D glucan, a kit and a detection method of fungus (1-3)-beta-D glucan, and belongs to the technical field of biomedical detection. The serum sample treatment liquid comprises a carbonate buffer solution with the pH value of 9.5-10.5, bacillus licheniformis protease, CHAPS, a surfactant and a preservative. The protein denaturing agent stop buffer comprises a phosphate buffer, a protease inhibitor, BSA and other components. Under the mild weak alkaline condition, the combined action of protease and a denaturant is utilized, a fungus (1-3)-beta-D glucan antigen-antibody compound in serum is efficiently dissociated, an antibody is irreversibly inactivated, and meanwhile the antigen activity is kept. The method has the advantages of simple operation, no need of heating, centrifugation or strong corrosive reagents, high safety, no precipitation and no gel of the treated sample, and suitableness for subsequent immunological detection. The invention further provides a detection kit containing the solution and a corresponding detection method, and the detection accuracy and efficiency are remarkably improved.

This invention discloses a method and sensor for adiponectin detection using a polyaniline and polyacrylic acid-modified wire mesh carbon electrode, relating to the field of adiponectin detection technology. The method involves electrochemically activating the wire mesh carbon electrode, electropolymerizing it to form a polyaniline-polyacrylic acid composite modification layer, immobilizing adiponectin monoclonal antibody after activation with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, blocking the antibody with bovine serum albumin, and reacting it with a serum sample. The adiponectin concentration is determined based on the peak potential shift and peak current change. This invention simultaneously achieves both conductive transport and antibody immobilization, reduces non-specific adsorption and serum interference, and improves detection sensitivity, repeatability, and quantitative accuracy.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

The application relates to a centrifugal device and method for detecting animal serum samples and relates to the technical field of serum sample detection. The device comprises a body, a spline is rotationally connected to the bottom of the body cavity through a motor, a bracket is connected to the upper end of the spline in a concave-convex abutting mode, an electrically conductive slip ring is arranged on the outside of the motor output end of the bottom of the body cavity, and a stator on the outside of the electrically conductive slip ring is fixed in the cavity of the body through a connecting rod. Through cooperation of a clamping assembly, a sleeve, a clamping seat and a tube clamp, the clamping seat is driven to rotate by rotating the rotating sleeve, the tube clamp is opened and closed in an interlaced mode through meshing of the connecting plate and the gear, various sizes of serum test tubes can be clamped, special parts need not be replaced, work efficiency is improved, meanwhile, when the number of test tubes is odd, the gravity sensor senses the weight, the electric push rod pushes the connecting frame on the symmetrical position to adjust the position, the gravity center is adjusted through cooperation of the rotating structure, the bracket is balanced, sample spilling and pollution are avoided.

The invention relates to the technical field of biotechnology and medical detection, in particular to an ovarian cancer early-stage accurate screening method based on triple lipid metabolite chemical crosslinking, which comprises the following steps: sample collection: collecting a serum sample of a person to be detected; lipid metabolite extraction: extracting lipid metabolite from the serum sample; detection of triple lipid metabolites: simultaneously detecting the contents of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) in the lipid metabolites by adopting a liquid chromatography-mass spectrometry technology, and by simultaneously detecting the three lipid metabolites of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) and carrying out chemical cross-linking analysis, the content of the triple lipid metabolites in the lipid metabolites can be detected; and calculating the triple lipid metabolite index (TLMI), so that the abnormal lipid metabolism condition of the ovarian cancer patient can be more comprehensively and accurately reflected, and the sensitivity and the specificity of early screening of the ovarian cancer are improved.

The invention belongs to the technical field of biomedical detection, and particularly discloses a nucleic acid aptamer for specifically recognizing serum alpha fetoprotein and application of the nucleic acid aptamer. The nucleotide sequence of the nucleic acid aptamer comprises a sequence as shown in SEQ ID No.1, or has more than 90% of homology with the sequence as shown in SEQ ID No.1, or one or more nucleotides are deleted or added in the sequence as shown in SEQ ID No.1. The nucleic acid aptamer can realize specific efficient recognition of AFP protein, also shows extremely high selectivity in a complex serum sample environment, eliminates non-specific adsorption interference of homologous protein and other serum interference protein, greatly reduces the false positive rate, and improves the accuracy and specificity of clinical detection. And the material constructed by directionally functionalizing the aptamer on the surface of the magnetic nano-carrier has rapid magnetic response performance, separation and enrichment of target protein can be realized within seconds, and the clinical diagnosis time is greatly shortened.

The invention relates to an intramolecular strand displacement reaction-based microRNA detection method and kit, and the kit is characterized in that the kit comprises four single-stranded sequences forming a DNA tetrahedron, a probe S and DNA polymerase; a probe T structure is designed at the top end of the DNA tetrahedron, and the probe T is used for capture of the probe S and intramolecular strand displacement reaction triggered by microRNA to be detected. The DNA tetrahedral structure is utilized to enhance the probe fixing efficiency and stability, and the detection sensitivity is improved; signal amplification is realized through intramolecular strand displacement reaction, and the detection limit is as low as 5 * 10 <-17 > mol / L; good selectivity is achieved, and single-base mismatch sequences can be distinguished; the kit has good performance in serum samples and has practical application potential.

The application relates to an electrochemical sensor based on antibody-aptamer synergic recognition and a construction method and application thereof, and belongs to the technical field of electrochemical analysis and biomarker AZGP1 detection technology. The sensor has strong resistance to high-concentration endogenous interference, and has good selectivity when interference and AZGP1 exist. Compared with the prior art, the sensor has the advantages of high sensitivity, high selectivity, simple operation, rapid detection, low cost and the like, and successfully realizes the detection of AZGP1 in a clinical patient serum sample, and provides a new and efficient method for clinical detection of biological recognition molecules.

The invention discloses a detection method of vitamin K1, and belongs to the technical field of biological detection. The problems that a vitamin K1 detection method is tedious in operation, prone to being influenced by a matrix, low in sensitivity and the like are solved. The detection method comprises the following steps: (1) preparing a standard substance intermediate working solution, an isotope internal standard substance solution and a standard curve working solution of the vitamin K1; (2) treating a serum sample and a standard curve working solution: adding a 2-nitroso pyridine solution to carry out derivatization reaction; and (3) detecting the vitamin K1 by using a high performance liquid chromatography-tandem mass spectrometry method. According to the method, the 2-nitroso pyridine is used as a derivatization reagent, the vitamin K1 and the 2-nitroso pyridine are subjected to a Diels-Alder reaction to generate a new six-membered heterocycle containing N and O, the 2-nitroso pyridine can efficiently and completely react with the vitamin K1 in only 10 minutes at room temperature, the detection steps are simplified, the sample pretreatment time is shortened, and the detection efficiency is improved.

The invention discloses a cascade seven-core optical fiber sensor applied to folic acid detection and a preparation method of the cascade seven-core optical fiber sensor, and belongs to the technical field of optical fiber sensing and biological analysis detection. The sensor comprises a first single-mode optical fiber, a seven-core optical fiber section and a second single-mode optical fiber, a double-microsphere-cavity structure is arranged at the optical fiber connecting position to form a cascade interference optical path, and tapering is conducted on the middle portion of the seven-core optical fiber section to form a sensing area. According to the invention, mode matching is improved through the microsphere cavity, an evanescent field is enhanced through tapering, and high-sensitivity specific detection of folic acid is realized in cooperation with the folic acid binding protein biological functional layer fixed on the surface; the sensor obtains stable linear response to a folic acid standard solution in the range of 0-50 ng / mL, a clinical serum sample verifies that the detection result of the sensor is highly consistent with that of a chemiluminescence method, the sensor has good reusability, and the sensor has the advantages of being easy to prepare in structure, rapid in response, high in sensitivity, capable of being matched with a complex matrix and the like, and has good application prospects. The method has huge potential in clinical folic acid quantitative detection.

The invention discloses a blocking agent for cell immunofluorescence detection by a slide method and a use method of the blocking agent. The blocking agent is a homologous no-load cell lysis solution without transfection plasmids, and the protein concentration is greater than or equal to 30mg / mL. The blocking agent is completely the same as cell cytoplasm and cell membrane components of cells to be detected except for plasmids-expressed antigens, when in use, the blocking agent is pre-mixed with a blood cleaning sample in advance, interfering antibodies except target antibodies in serum can be purified, and meanwhile, due to the fact that no antigen protein expressed after plasmid transfection exists, the blocking agent can be used for detecting the cells to be detected. And the protein concentration is equivalent to the globulin concentration in serum, so that the target antibody cannot be lost in the serum, and the slide method CBA detection sensitivity can be greatly improved.

The invention discloses a detection method of a blood entering component of a Mongolian medicine Tiangu-3 for treating asthma, and relates to the technical field of medicine in-vivo metabolism, and the detection method specifically comprises the following steps: S1, collection of a biological sample: respectively collecting initial blank serum and drug-containing serum for later use; s2, preparation of a biological sample: treating the initial blank serum and the drug-containing serum to obtain blank serum and drug administration serum samples for later use; s3, preparing an in-vitro test sample, namely treating daily check-3 to obtain a traditional Chinese medicine sample for later use; and S4, respectively taking the blank serum, the administration serum and 10 mu L of the traditional Chinese medicine sample, carrying out LC-MS / MS analysis, and determining the in-blood components based on the detection result. The method disclosed by the invention can more comprehensively reveal the characteristics of the drug-derived components after the drug enters the blood, and fills the blank in the fields of qualitative analysis of the components entering the blood and quantitative detection of all the effective components in the Jiaogue-3 (Jiaogue-3) (Jiaogue-3) (Jiaogue-3).

The invention provides an anti-double-stranded DNA antibody indirect immunofluorescence method picture interpretation method and device and a medium, and the method comprises the following steps: obtaining a to-be-collected slide which is obtained by treating a to-be-detected serum sample through an anti-double-stranded DNA indirect immunofluorescence method; performing image acquisition on the to-be-acquired slide to obtain an acquired image set corresponding to the to-be-acquired slide; performing image processing on the acquired image set to obtain a first target image set; performing image processing on the first target image set to obtain a cell region corresponding to each first target image in the first target image set; and performing identification processing on the cell region corresponding to each first target image to obtain a sample report of the to-be-collected slide. According to the method, a series of steps of image acquisition, processing, cell region identification and the like are adopted for processing, so that the traditional manual operation is replaced, the automation of the interpretation process is realized, and the interpretation accuracy and efficiency are improved.

The invention discloses a biosensor based on an ultraviolet light triggered bio-barcode release technology (OBCA) and construction and application of the biosensor. The biosensor comprises nucleic acid functionalized silver nanoparticles, nucleic acid functionalized magnetic beads and a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas12a detection system, the DNA bar code modified on the surface of the silver nanoparticle contains a light cleavable linker, a CRISPR / Cas12a activation sequence and a target capture sequence I, and a DNA capture probe containing a target capture sequence II is fixed on the surface of the magnetic bead through biotin-streptavidin action. During detection, target miRNA mediates two capture sequences to form a sandwich compound, after magnetic separation and thermal denaturation elution, 365nm ultraviolet radiation releases DNA bar code fragments, and the Cas12a trans-cleavage fluorescence quenching reporter probe is activated to generate a signal. According to the method, nucleic acid amplification and reverse transcription are not needed, the detection limits of miR-21, miR-155 and mi-210 respectively reach 158.94 aM, 763.56 aM and 197.82 aM, single-base mismatch and precursor miRNA can be distinguished, the serum sample detection result is highly consistent with that of RT-PCR, and the method is suitable for high-sensitivity quantitative detection of miRNA.

A system for whole blood sampling and separation includes a blood draw device coupled to a catheter assembly, with the blood draw device including a catheter tube, a housing that movably receives the catheter tube, and an advancement member to move the catheter tube between first and second positions, to enable a distal end of the catheter tube to be disposed within or past a distal tip of an indwelling catheter. A blood separation device is attached to the blood draw device to directly receive a blood sample therefrom and comprises a centrifuge-free mechanism configured to separate a plasma or serum sample from the blood sample. A sample collection container is coupled with the separation device and provides a vacuum pressure that draws the blood sample into the separation device, with the separated plasma or serum sample being drawn into the sample collection container.

This invention relates to an IL5 / Bi2MoO6 / MXene photoactive composite material, a low-background photoelectrochemical aptamer sensor, its preparation method, and its applications. The sensor is constructed by sequentially modifying chitosan, glutaraldehyde, complementary DNA strands, and a gold nanoparticle-labeled aptamer. A fixed capture probe and APT-Au synergistically achieve dual signal quenching, constructing an extremely low detection baseline. When the target analyte MUC1 is present, its specific binding to the aptamer causes APT-Au to detach, dissolving the dual quenching and significantly restoring the photocurrent, thereby achieving quantitative detection. This invention solves the problems of low efficiency, heterojunction instability, and high baseline in single quenching modes of existing photoelectric materials, achieving highly sensitive, highly specific, rapid, and low-cost detection of the breast cancer biomarker MUC1 in human serum samples, providing a novel, industrially feasible technical solution for large-scale early screening of breast cancer.

The invention relates to the field of medical informatics, and provides a biomarker-based thyroid nodule benign and malignant identification method and system. The method comprises the following steps: collecting a serum sample; performing quantitative detection on the multiple markers in the serum sample to obtain concentration data of the multiple markers; inputting the multi-marker concentration data into a pre-constructed probability calculation model to obtain a prediction probability value; and according to a preset diagnosis threshold value and the prediction probability value, judging whether the thyroid nodule is benign or malignant to obtain a thyroid nodule benign or malignant identification result. By integrating multi-marker information, the biological difference between benign and malignant nodules is effectively captured, and the overall efficiency of differential diagnosis is improved.

This invention belongs to the fields of molecular biology and bioinformatics, specifically relating to a truncated bovine virus-encoded protein phage library, its construction method, and applications. This library covers all 162 known bovine viruses that host bovine subfamily viruses, containing 51,794 non-redundant peptide coding sequences of 56 amino acids each. These peptides are fused and displayed on the surface of the T7 phage capsid, with all coding sequences having a uniform total length of 200 bp. The library construction was achieved through sequence acquisition, truncation and redundancy removal, codon optimization and DNA synthesis, and in vitro ligation and packaging with T7 phage. The resulting library exhibits a positivity rate of 93% and a titer of 2.8 × 10⁻⁶. 10 PFU / mL. This invention features an optimized single-round high-throughput screening process adapted to clinical bovine serum samples, enabling efficient identification of bovine virus B-cell epitopes and providing tools and candidate targets for bovine virus vaccine development and diagnostic reagent development.

A method capable of determining a probability of a subject having one or multiple cancer tissues of origin is disclosed. The method includes inputting the expression profile of a miRNA set obtained from a biopsy sample such as serum sample of the subject into a classifier which is based on a machine learning model such as a support vector machine model. In certain embodiments, the method can be used to simultaneously determine the probability of the subject having each of multiple different cancer types, which can enhance the prediction accuracy.

The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.

The invention belongs to the field of medicine, and relates to a construction method of a pneumonia severity prediction model and the prediction model.The construction method comprises the steps that 1, a serum sample of a patient infected by mycoplasma pneumonia is obtained; 2) detecting the content of S100A8 / A9 protein in the serum sample; 3) establishing a data set according to the patient infected by mycoplasma pneumonia, wherein the data set comprises a training set and a verification set; 4) constructing a regression model for the content of the S100A8 / A9 protein by adopting a lasso regression mode; and 5) training the regression model by using the training set to obtain a pneumonia severity prediction model. The invention provides the construction method of the pneumonia severity prediction model which has good prediction performance and good clinical applicability and can improve the accuracy of risk stratification of mycoplasma pneumonia patients, and the prediction model.